The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott ...

Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated ...

VX-880 stem cell therapy led to 92% reduction in insulin use, with 10 out of 12 patients eliminating injections entirely in a ...

For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated ...

Women with diabetes who were overweight or had obesity lost more weight and had greater odds of diabetes remission when ...

Most in a small group of patients receiving a stem cell-based infusion no longer needed insulin, but the drug may not suit ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Results presented at the 85th Scientific Sessions of the American Diabetes Association in Chicago highlight the potential for ...

All 3 doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40.

CHICAGO, June 21, 2025 /PRNewswire/ -- As the American Diabetes Association® (ADA) celebrates its 85th anniversary, it continues to fuel transformative progress in the fight to end diabetes—and ...